Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 3, 2010, Pages 289-302

  Kanazawa, Takeharu ^a,b   Misawa, Kiyoshi ^a,c   Carey, Thomas E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiproliferative effect; Apoptosis; Galanin; GPCR; Head and neck neoplasm; P53 independent pathway

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1C; GALANIN RECEPTOR 1; GALANIN RECEPTOR 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P53;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CELL TYPE; EPIGENETICS; GENE THERAPY; GENETIC TRANSDUCTION; HEAD AND NECK CARCINOMA; HUMAN; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG DELIVERY SYSTEMS; GALANIN; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR BIOLOGY; RECEPTOR, GALANIN, TYPE 1; RECEPTOR, GALANIN, TYPE 2; SIGNAL TRANSDUCTION;

EID: 77149177951     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728221003598922     Document Type: Review

References (100)

1. Frank CJ, McClatchey KD, Devaney KO, Carey TE. Evidence that loss of chromosome 18q is associated with tumor progression. Cancer Res 1997;57(5):824-827
2. Pearlstein RP, Benninger MS, Carey TE, et al. Loss of 18q predicts poor survival of patients with squamous cell carcinoma of the head and neck. Genes Chromosomes Cancer 1998;21(4):333-339
3. Takebayashi S, Ogawa T, Jung KY, et al. Identification of new minimally lost regions on 18q in head and neck squamous cell carcinoma. Cancer Res 2000;60(13):3397-3403
4. Tatemoto K, Rokaeus A, Jornvall H, et al. Galanin - a novel biologically active peptide from porcine intestine. FEBS Lett 1983;164(1):124-128
5. Leibowitz SF. Regulation and effects of hypothalamic galanin: Relation to dietary fat, alcohol ingestion, circulating lipids and energy homeostasis. Neuropeptides 2005;39(3):327-332
6. Holmes FE, Mahoney SA, Wynick D. Use of genetically engineered transgenic mice to investigate the role of galanin in the peripheral nervous system after injury. Neuropeptides 2005;39(3):191-199
7. Kanazawa T, Iwashita T, Kommareddi P, et al. Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: Activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors. Oncogene 2007;26(39):5762-5771
8. Kanazawa T, Kommareddi PK, Iwashita T, et al. Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells. Clin Cancer Res 2009;15(7):2222-2230
9. Branchek TA, Smith KE, Gerald C, Walker MW. Galanin receptor subtypes. Trends Pharmacol Sci 2000;21(3):109-117
10. Lang R, Gundlach AL, Kofler B. The galanin peptide family: Receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther 2007;115(2):177-207
11. Habert-Ortoli E, Amiranoff B, Loquet I, et al. Molecular cloning of a functional human galanin receptor. Proc Natl Acad Sci USA 1994;91(21):9780-9783
12. Wang S, Hashemi T, Fried S, et al. Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes. Biochemistry 1998;37(19):6711-6717 (Pubitemid 28228104)
13. Smith KE, Walker MW, Artymyshyn R, et al. Cloned human and rat galanin GALR3 receptors. Pharmacology and activation of G-protein inwardly rectifying K+ channels. J Biol Chem 1998;273(36):23321-23326
14. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008;14(2):342-346
15. Henson BS, Neubig RR, Jang I, et al. Galanin receptor 1 has anti-proliferative effects in oral squamous cell carcinoma. J Biol Chem 2005;280(24):22564-22571
16. Gutkind JS. The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J Biol Chem 1998;273(4):1839-1842
17. Seufferlein T, Rozengurt E. Galanin, neurotensin, and phorbol esters rapidly stimulate activation of mitogen-activated protein kinase in small cell lung cancer cells. Cancer Res 1996;56(24):5758-5764
18. Mochizuki N, Ohba Y, Kiyokawa E, et al. Activation of the ERK/MAPK pathway by an isoform of rap1GAP associated with G alpha(i). Nature 1999;400(6747):891-894
19. Fathi Z, Cunningham AM, Iben LG, et al. Cloning, pharmacological characterization and distribution of a novel galanin receptor. Brain Res Mol Brain Res 1997;51(1-2):49-59
20. Smith KE, Forray C, Walker MW, et al. Expression cloning of a rat hypothalamic galanin receptor coupled to phosphoinositide turnover. J Biol Chem 1997;272(39):24612-24616
21. Wang S, Clemmons A, Strader C, Bayne M. Evidence for hydrophobic interaction between galanin and the GalR1 galanin receptor and GalR1-mediated ligand internalization: Fluorescent probing with a fluorescein-galanin. Biochemistry. 1998;37(26):9528-9535
22. Fathi Z, Battaglino PM, Iben LG, et al. Molecular characterization, pharmacological properties and chromosomal localization of the human GALR2 galanin receptor. Brain Res Mol Brain Res 1998;58(1-2):156-169
23. Wang S, Hashemi T, He C, et al. Molecular cloning and pharmacological characterization of a new galanin receptor subtype. Mol Pharmacol 1997;52(3):337-343 (Pubitemid 27412957)
24. Hawes JJ, Narasimhaiah R, Picciotto MR. Galanin and galanin-like peptide modulate neurite outgrowth via protein kinase C-mediated activation of extracellular signal-related kinase. Eur J Neurosci 2006;23(11):2937-2946
25. Hobson SA, Holmes FE, Kerr NC, et al. Mice deficient for galanin receptor 2 have decreased neurite outgrowth from adult sensory neurons and impaired pain-like behaviour. J Neurochem 2006;99(3):1000-1010
26. Elliott-Hunt CR, Pope RJ, Vanderplank P, Wynick D. Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage. J Neurochem 2007;100(3):780-789
27. Moelling K, Schad K, Bosse M, et al. Regulation of Raf-Akt Cross-talk. J Biol Chem 2002;277(34):31099-31106
28. Suzuki K, Suzuki I, Leodolter A, et al. Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell 2006;9(3):199-207
29. Iismaa TP, Fathi Z, Hort YJ, et al. Structural organization and chromosomal localization of three human galanin receptor genes. Ann N Y Acad Sci 1998;863:56-63
30. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6(2):107-116
31. Verma M, Srivastava S. Epigenetics in cancer: Implications for early detection and prevention. Lancet Oncol 2002;3(12):755-763
32. Misawa K, Ueda Y, Kanazawa T, et al. Epigenetic inactivation of galanin receptor 1 in head and neck cancer. Clin Cancer Res 2008;14(23):7604-7613
33. Chung W, Kwabi-Addo B, Ittmann M, et al. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One 2008;3(4):e2079
34. Bauer FE, Hacker GW, Terenghi G, et al. Localization and molecular forms of galanin in human adrenals: elevated levels in pheochromocytomas. J Clin Endocrinol Metab 1986;63(6):1372-1378
35. Hulting AL, Meister B, Grimelius L, et al. Production of a galanin-like peptide by a human pituitary adenoma: Immunohistochemical evidence. Acta Physiol Scand 1989;137(4):561-562
36. Leung B, Iisma TP, Leung KC, et al. Galanin in human pituitary adenomas: Frequency and clinical significance. Clin Endocrinol (Oxf) 2002;56(3):397-403
37. Bennet WM, Hill SF, Ghatei MA, Bloom SR. Galanin in the normal human pituitary and brain and in pituitary adenomas. J Endocrinol 1991;130(3):463-467
38. Grenback E, Bjellerup P, Wallerman E, et al. Galanin in pituitary adenomas. Regul Pept 2004;117(2):127-139
39. Ormandy CJ, Lee CS, Ormandy HF, et al. Amplification, expression, and steroid regulation of the preprogalanin gene in human breast cancer. Cancer Res 1998;58(7):1353-1357
40. Berger A, Lang R, Moritz K, et al. Galanin receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma cells. Endocrinology 2004;145(2):500-507
41. Tjomsland V, El-Salhy M. Effects of single, double or triple combinations of octreotide, galanin and serotonin on a human pancreatic cancer cell line. Histol Histopathol 2005;20(2):537-541 (Pubitemid 40468274)
42. Hammond PJ, Smith DM, Akinsanya KO, et al. Signalling pathways mediating secretory and mitogenic responses to galanin and pituitary adenylate cyclase-activating polypeptide in the 235-1 clonal rat lactotroph cell line. J Neuroendocrinol 1996;8(6):457-464
43. Iishi H, Tatsuta M, Baba M, et al. Chemoprevention by galanin against colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 1995;61(6):861-863
44. Iishi H, Tatsuta M, Baba M, et al. Inhibition by galanin of experimental carcinogenesis induced by azaserine in rat pancreas. Int J Cancer 1998;75(3):396-399
45. El-Salhy M, Dennerqvist V. Effects of triple therapy with octreotide, galanin and serotonin on liver metastasis of human colon cancer in xenografts. Oncol Rep 2004;11(6):1177-1182
46. El-Salhy M, Tjomsland V, Theodorsson E. Effects of triple treatment with octreotide, galanin and serotonin on a human pancreas cancer cell line in xenografts. Histol Histopathol 2005;20(3):745-752 (Pubitemid 40932592)
47. McDonald AC, Schuijers JA, Shen PJ, et al. Expression of galanin and galanin receptor-1 in normal bone and during fracture repair in the rat. Bone 2003;33(5):788-797
48. Takebayashi S, Hickson A, Ogawa T, et al. Loss of chromosome arm 18q with tumor progression in head and neck squamous cancer. Genes Chromosomes Cancer 2004;41(2):145-154
49. Ferbeyre G, De Stanchina E, Lin AW, et al. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 2002;22(10):3497-3508
50. Lahlou H, Saint-Laurent N, Esteve JP, et al. sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 2003;278(41):39356-39371
51. Dixon BS, Evanoff D, Fang WB, Dennis MJ. Bradykinin B1 receptor blocks PDGF-induced mitogenesis by prolonging ERK activation and increasing p27Kip1. Am J Physiol Cell Physiol 2002;283(1):C193-203
52. Otis M, Campbell S, Payet MD, Gallo-Payet N. Angiotensin II stimulates protein synthesis and inhibits proliferation in primary cultures of rat adrenal glomerulosa cells. Endocrinology 2005;146(2):633-642
53. Pumiglia KM, Decker SJ. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA 1997;94(2):448-452
54. Tsukada Y, Miyazawa K, Kitamura N. High intensity ERK signal mediates hepatocyte growth factor-induced proliferation inhibition of the human hepatocellular carcinoma cell line HepG2. J Biol Chem 2001;276(44):40968-40976
55. Han J, Tsukada Y, Hara E, et al. Hepatocyte growth factor induces redistribution of p21(CIP1) and p27 (KIP1) through ERK-dependent p16 (INK4a) up-regulation, leading to cell cycle arrest at G1 in HepG2 hepatoma cells. J Biol Chem 2005;280(36):31548-31556
56. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78(1):67-74
57. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57(16):3381-3385
58. Hoffmann MJ, Florl AR, Seifert HH, Schulz WA. Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer 2005;114(3):406-413
59. Massarelli E, Brown E, Tran NK, et al. Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer 2005;103(5):952-959
60. Kong S, Amos CI, Luthra R, et al. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 2000;60(2):249-252
61. Akervall J, Bockmuhl U, Petersen I, et al. The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1: CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck. Clin Cancer Res 2003;9(5):1750-1755
62. Wittau N, Grosse R, Kalkbrenner F, et al. The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to G(q), G(i) and G(12) proteins. Oncogene 2000;19(37):4199-4209
63. Sugimoto T, Seki N, Shimizu S, et al. The galanin signaling cascade is a candidate pathway regulating oncogenesis in human squamous cell carcinoma. Genes Chromosomes Cancer 2009;48(2):132-142
64. Tofighi R, Joseph B, Xia S, et al. Galanin decreases proliferation of PC12 cells and induces apoptosis via its subtype 2 receptor (GalR2). Proc Natl Acad Sci USA 2008;105(7):2717-2722
65. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282(5392):1318-1321
66. Zha J, Harada H, Yang E, et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996;87(4):619-628
67. Shibata MA, Yoshidome K, Shibata E, et al. Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Ther 2001;8(1):23-35
68. Los M, Stroh C, Janicke RU, et al. Caspases: More than just killers? Trends Immunol 2001;22(1):31-34
69. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1(8):639-649
70. Wang X, Gorospe M, Huang Y, Holbrook NJ. p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 1997;15(24):2991-2997
71. Otsubo T, Akiyama Y, Yanagihara K, Yuasa Y. SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer 2008;98(4):824-831
72. Putzer BM, Stiewe T, Parssanedjad K, et al. E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products. Cell Death Differ 2000;7(2):177-188
73. Urist M, Tanaka T, Poyurovsky MV, Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev 2004;18(24):3041-3054
74. Wang P, Gao H, Ni Y, et al. Beta-arrestin 2 functions as a G-protein-coupled receptor-activated regulator of oncoprotein Mdm2. J Biol Chem 2003;278(8):6363-6370
75. Lasfer M, Vadrot N, Schally AV, et al. Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238. J Hepatol 2005;42(2):230-237
76. Hill SJ. G-protein-coupled receptors: past, present and future. Br J Pharmacol 2006; 147 (Suppl 1):S27-37
77. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26(19):3128-3137
78. Kumar B, Cordell KG, D'Silva N, et al. Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 2008;134(4):363-369
79. Yu J, Zhou H, Jin Y, et al. Three distinct regions of allelic deletion on chromosome 17 involved in sporadic gastric cancer. Hepatogastroenterology 2008;55(85):1487-1491
80. Yu JC, Zhou H, Bai J, et al. Human gastric adenocarcinoma allelotype on chromosomes 17 and 18. J Int Med Res 2008;36(2):279-288
81. Landry M, Holmberg K, Zhang X, Hokfelt T. Effect of axotomy on expression of NPY, galanin, and NPY Y1 and Y2 receptors in dorsal root ganglia and the superior cervical ganglion studied with double-labeling in situ hybridization and immunohistochemistry. Exp Neurol 2000;162(2):361-384
82. Lundstrom L, Elmquist A, Bartfai T, Langel U. Galanin and its receptors in neurological disorders. Neuromolecular Med 2005;7(1-2):157-180
83. Shen PJ, Larm JA, Gundlach AL. Expression and plasticity of galanin systems in cortical neurons, oligodendrocyte progenitors and proliferative zones in normal brain and after spreading depression. Eur J Neurosci 2003;18(6):1362-1376
84. Mazarati A, Lu X, Kilk K, et al. Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. Eur J Neurosci 2004;19(12):3235-3244
85. Mitsukawa K, Lu X, Bartfai T. Galanin, galanin receptors and drug targets. Cell Mol Life Sci 2008;65(12):1796-1805
86. Bartfai T, Lu X, Badie-Mahdavi H, et al. Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc Natl Acad Sci USA 2004;101(28):10470-10475
87. El-Salhy M, Sitohy B. Triple therapy with octreotide, galanin and serotonin induces necrosis and increases apoptosis of a rat colon carcinoma. Regul Pept 2002;108(2-3):55-62
88. Merino OR, Lindberg RD, Fletcher GH. An analysis of distant metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 1977;40(1):145-151
89. Clayman GL, el-Naggar AK, Roth JA, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995;55(1):1-6
90. Yoo GH, Moon J, Leblanc M, et al. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: Report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg 2009;135(9):869-874
91. Barzon L, Pacenti M, Taccaliti A, et al. A pilot study of combined suicide/cytokine gene therapy in two patients with end-stage anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2005;90(5):2831-2834
92. Gleich LL, Gluckman JL, Nemunaitis J, et al. Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001;127(7):775-779
93. Berns KI, Rose JA. Evidence for a single-stranded adenovirus-associated virus genome: Isolation and separation of complementary single strands. J Virol 1970;5(6):693-699
94. Moss RB, Milla C, Colombo J, et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: A randomized placebo-controlled phase 2B trial. Hum Gene Ther 2007;18(8):726-732
95. Ozawa K, Fan DS, Shen Y, et al. Gene therapy of Parkinson's disease using adeno-associated virus (AAV) vectors. J Neural Transm Suppl 2000;(58):181-191 (Pubitemid 30943176)
96. Ishiwata A, Mimuro J, Mizukami H, et al. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice. J Gene Med 2009;11(11):1020-1029
97. Kanazawa T, Mizukami H, Okada T, et al. Suicide gene therapy using AAV-HSVtk/ ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther 2003;10(1):51-58
98. Kanazawa T, Mizukami H, Nishino H, et al. Topoisomerase inhibitors enhance the cytocidal effect of AAV-HSVtk/ ganciclovir on head and neck cancer cells. Int J Oncol 2004;25(3):729-735
99. Lin EJ, Richichi C, Young D, et al. Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur J Neurosci 2003;18(7):2087-2092
100. McCown TJ. Adeno-associated virus vector-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity. Neurotherapeutics 2009;6(2):307-311